ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
(BULLETIN BOARD: GOVX) , an Atlanta based, publicly traded
biopharmaceutical company specializing in the prevention and
treatment of infectious diseases, presented data on their AIDS
vaccine (trial HVTN 065) at the AIDS Vaccine 2008 conference, on
October 15 in Cape Town, South Africa. This conference comes at
an exciting time for GeoVax, which is preparing to enter Phase 2
trials for its vaccine.
The presentation, titled "Two HIV DNA Primes Maximize T Cell
Responses Induced by the GeoVax DNA/MVA Vaccine Regimen
Administered to Healthy Seronegative Adults (HVTN 065)," was
given by Dr. Paul A. Goepfert, M.D., Associate Professor,
Division of Infectious Diseases, Department of Medicine,
University of Alabama. Dr. Goepfert is the HVTN 065 Protocol
Team chair. The trial results reveal the GeoVax DNA and MVA
vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune
responses) at both low (1/10th) dose and full doses. Other
-- GeoVax vaccines were well tolerated with no or mild local and
systemic reactions in the majority of trial participants.
-- 80 percent of both the low and full dose trial participants
responded to the vaccine which stimulated anti-HIV T-cell (white
blood cell) and antibody responses.
-- More volunteers had antibody responses to the full dose than
to the 1/10th dose vaccine, whereas response rates for T cells
were similar for the 1/10th and full dose.
-- Two DNA primes were more effective than one DNA prime or no
DNA primes at eliciting T cell responses.
-- The 2nd MVA vaccination positively increased CD8 T cell and
"As the entire world tries to find a solution for the HIV/AIDS
crisis, GeoVax, a front runner in the search for an effective
vaccine, is on the verge of entering Phase 2 trials," said Bob
McNally, CEO and President of GeoVax Labs, Inc. "The AIDS
Vaccine 2008 conference is a meeting of the minds and it gives
hope to humankind that we are making progress on finding a
solution to this worldwide epidemic."
The Phase 2a trial will be conducted by the U.S. National
Institutes of Health (NIH) supported HIV Vaccine Trials Network
(HVTN) and will involve 225 healthy volunteers from the United
States and South America. The trial will further evaluate the
safety and immunogenicity of the GeoVax preventative vaccine
(vaccine administered prior to infection with the HIV virus).
The larger Phase 2 human trial will broaden the base of safety
and immunogenicity data for the full dose of the GeoVax AIDS
Dr. Harriet Robinson, the developer of the vaccine and GeoVax's
Vice President of Research and Development, also presented these
same results at the Viral Vector Vaccines 2008 meeting, at the
Wellcome Trust Conference Center near Cambridge, UK, on September
The AIDS Vaccine 2008 conference is held by the Global HIV
Vaccine Enterprise, an alliance of independent organizations
around the world dedicated to accelerating the development of a
preventive HIV vaccine by:
-- Shared Scientific Plan: Implementing a strategic plan for HIV
vaccine research that spans vaccine discovery, product
development and manufacturing, and clinical trials
-- Increased Resources: Mobilizing significant new funding to
achieve the scientific plan
-- Greater Collaboration: Promoting more efficient, faster ways
for researchers to share successes and failures and avoid
duplication of efforts.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to
develop, manufacture, license and commercialize human vaccines
for diseases caused by HIV-1 (Human Immunodeficiency Virus) and
other infectious agents. GeoVax's AIDS vaccine technology is the
subject of 20 issued or filed patent applications. GeoVax AIDS
vaccines are designed for use in uninfected people to prevent
Acquired Immunodeficiency Disease (AIDS), caused by the virus
known as HIV-1, should the person ever become infected. GeoVax
AIDS vaccines also may be effective as therapeutics, treatment of
people already infected with AIDS virus.
GeoVax's core AIDS vaccine technologies were developed by Dr.
Harriet Robinson, Senior V.P. of Research and Development,
through a collaboration of colleagues at Emory University's
Vaccine Center, the National Institutes of Health (NIH), The
Centers for Disease Control and Prevention (CDC) and GeoVax.
GeoVax AIDS vaccines have moved forward in human clinical trials
conducted by the HIV Vaccine Trials Network (HVTN) based in
Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health (NIH), is the
largest worldwide clinical trials program dedicated to the
development and testing of AIDS vaccines. Preclinical work
enabling evaluation of GeoVax DNA and MVA vaccines was funded and
supported by NIAID, which provided additional support to GeoVax
AIDS vaccine development program with a $15 million IPCAVD grant
awarded in late 2007.
Safe Harbor Statement: All statements in this news release, not
statements of historical fact, are forward-looking statements.
These statements are based on expectations and assumptions on the
date of this press release and are subject to numerous risks and
uncertainties which could cause actual results to differ
materially from those described in the forward-looking
statements. Risks and uncertainties include, but are not limited
to, whether: GeoVax can develop and manufacture these vaccines
with the desired characteristics in a timely manner, GeoVax's
vaccines will be safe for human use, GeoVax's vaccines will
effectively prevent AIDS in humans, vaccines will receive
regulatory approvals necessary to be licensed and marketed,
GeoVax raises required capital to complete vaccine development,
there is development of competitive products that may be more
effective or easier to use than GeoVax's products, and other
factors over which GeoVax has no control. GeoVax assumes no
obligation to update these forward-looking statements, and does
not intend to do so. Certain matters discussed in this news
release are forward-looking statements involving certain risks
and uncertainties including, without limitation, risks detailed
in the Company's Securities and Exchange Commission filings and
Source: GeoVax Labs, Inc.
CONTACT: Melanie Nimrodi of Financial Relations Board,
+1-312-546-3508, firstname.lastname@example.org, for GeoVax Labs, Inc.; or
Bob McNally of GeoVax Labs, Inc., +1-404-727-0971,